Gsk Share Discussion Threads

[cocopah] 09/2/2022 23:09

Good to get clarity on the divi … yes it will be lower for 2022 … probably there will be opportunity to trade the dips on the share price … or just hold and enjoy the growth from 2023 onwards. Depending on one’s entry price still worth holding in the ISA against other available plays IMHO. 🤷‍a94;️👍🏻😎

[daneswooddynamo] 09/2/2022 20:03

I think he is staying as a non-exec, I am hoping that is still a partially positive sign of his faith in his choices…

[essentialinvestor] 09/2/2022 19:44

danes, agree, but as you will be aware Hal has departed!.

[spoole5] 09/2/2022 19:09

No one believes the growth promises, if they did this would be on 20x earnings

[jonjoneil] 09/2/2022 18:06

"This is going to be a landmark year for GSK, with a step-change in growth expected.”

That's it then. Either she delivers this year, or she's out - no question If she screws up, I just hope they don't let her do like her failed predecessor did and line up her own successor!

[tradermichael] 09/2/2022 15:00

Pay-out ratios for 2022:

New GSK no change
CH 30-50%

[tradermichael] 09/2/2022 14:59

So, they say for 2022, dividend (combined) will be 49p/share, with New GSK (44p) and CH (5p)

[daneswooddynamo] 09/2/2022 14:46

Not much changed for gsk, needs a couple of big results from mr Barron’s drug programme

[spoole5] 09/2/2022 14:11

The value achieved when the ULVR bid was reported will not be achieved for a long time.

[speedsgh] 09/2/2022 13:30

Becoming somewhat less attractive as an income play.

TOTAL FY 2021 - 80.00p

TOTAL FY 2022 (E) - 52.00p
H1 2021 (pre-demerger) - 27.00p (GSK 22.00p; consumer healthcare 5.00p)
H2 2021 (post-demerger) - 25.00p (GSK 22.00p; consumer healthcare 3.00p)

TOTAL FY 2023 (E) - ??.??p (GSK 45.00p; consumer healthcare ?.??p)

[tradermichael] 09/2/2022 13:28

Strong commercial execution drives growth across Pharmaceuticals, Vaccines and Consumer Healthcare (excluding brands divested/under review)

Pharmaceuticals £17.7 billion +4% AER, +10% CER; New and Specialty medicines £10 billion +20% AER, +26% CER; Respiratory +21% AER, +28% CER; Immuno-inflammation +22% AER, +29% CER; Oncology +31% AER, +37% CER; total HIV -2% AER, +3% CER

Vaccines £6.8 billion -3% AER, +2% CER; Shingrix £1.7 billion -13% AER, -9% CER
COVID-19 solutions sales £1.4 billion; Xevudy £958 million; pandemic adjuvant £447 million

Consumer Healthcare £9.6 billion -4% AER, stable CER (+4% excluding brands divested/under review)

[laurence llewelyn binliner] 09/2/2022 13:22

#TraderMicheael, indeed, that was my best guess as to how it will play out without any losses, free shares in Healthcare and the combined share price similar to the pre split old GSK price, and we receive the dividends from both..

We get what we get, but both will be profitable over time.. :o)

[spyder] 09/2/2022 13:22

—> TM
Sadly, Mr Market disagrees, now down 30p on the day.
The Q&A should be interesting, I hope the analysts give the Board a hard time.

[bull19] 09/2/2022 13:19

Fair point Phillis. But in the absence of a crystal ball, it's the best we can go off!

[tradermichael] 09/2/2022 13:18

I don't think the details are to be known until the run up to the actual split (mid-2022). The Capital Markets Day on 28 Feb may give a glimmer of information (they say 'detailed financial information', but I doubt it will go as far as split details.

[laurence llewelyn binliner] 09/2/2022 13:09

Post split, will shareholders qualify for the same amount of free shares in GSK healthcare and retain existing new GSK shares..? both with a combined share price similar to the pre-split price on the day of the split..? so we will get the dividend from both automatically..?

If I have that wrong, how will the split work for existing shareholders…?

[spoole5] 09/2/2022 13:05

Nope will probably be about 15!

[spoole5] 09/2/2022 13:04

Market giving it the treatment it deserves

[montedawnster] 09/2/2022 13:03

16.22 Some folk bought in too soon.

[phillis] 09/2/2022 13:00

Bull you seem to have overlooked the fact that the slimmed down business wont be at 1622p

But hey!

[jonjoneil] 09/2/2022 12:59

Just watched Emma on Ian King.

I needed dark glasses to watch her. Then I checked the share price. Something don't add up!

All that effort for nowt

[tradermichael] 09/2/2022 11:32

The main Key Fact:

An impressive set of results!

(Better than expected, beating forecasts)

[tradermichael] 09/2/2022 11:31

GlaxoSmithKline's key facts

Price/Earnings ratio (next 12 months): 13.8
10 year average Price/Earnings ratio: 13.9
Prospective dividend yield (next 12 months): 3.3%

[bull19] 09/2/2022 11:29

Estimate for next year, from RNS figures is 52p so 3.2%